Vantage logo

Biopharma takeovers dry up

If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?

Vantage logo

Biopharma buyouts still pricey

A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.